

AQUARIUS SURGICAL TECHNOLOGIES INC. (ASTI-CSE) ANNOUNCES PROPOSED PRIVATE PLACEMENT AND EXTENSION OF EXERCISE DATE OF SERIES "A" WARRANTS

Toronto; March 19, 2018. Aquarius Surgical Technologies Inc. (Symbol: ASTI – CSE) ("Aquarius" or the "Company") announced today that, subject to receipt of all relevant regulatory and other consents and approvals, it is proposing to raise up to CAD\$1 million by way of an exempt private placement to accredited investors.

The proposed private placement will be of units ("Unit(s)"), priced at CAD\$0.45 per Unit. Each Unit will comprise one (1) fully paid non-assessable common share ("Share(s)") and one Series "C" share purchase warrant ("Series "C" Warrant(s)"). Each Series "C" Warrant will be exercisable during a period of two (2) years from the date of issue at a price of CAD\$0.90, to acquire one (1) further Share. The Series "C" Warrants will contain a Callable feature, pursuant to which the Company has the right to call the Series "C" Warrants for exercise at any time while they are outstanding if the average closing price of the Shares on the market is at or above 216% of the exercise price (i.e. CAD\$1.95) for twenty (20) trading days in a period of thirty (30) consecutive trading days.

Additionally, Aquarius announces that the Board of Directors has resolved, subject to receipt of all relevant regulatory and other consents and approvals, to extend the Expiration Date of the Series "A" Warrants that were issued during 2017, by one year from their original expiry dates. The Series "A" Warrants were originally exercisable at the price of \$1.50 for a period of two years from their respective dates of issue, which will now be extended to three years from their original date of issue. The Series "A" Warrants, on exercise, will result in issuance of a Unit comprised of one fully paid Share and one Series "B" Warrant, exercisable during a period of one year from its date of issue at CAD\$2.50 to acquire a further Share. Each of the Series "A" Warrants and Series "B" Warrants, in the case of the latter on issuance, contain a callable feature pursuant to which the Company has the right to call the Series "A" Warrants or Series "B" Warrants, as the case may be, for exercise at any time while they are outstanding if the average closing price of the Shares on the market is at or above 130% of the exercise price (i.e. CAD\$1.95 in the case of the Series "A" Warrants or CAD\$3.25 in the case of the Series "B" Warrants) for twenty (20) trading days in a period of thirty (30) consecutive trading days.

About the Company.

Aquarius Surgical Technologies Inc., through its wholly-owned subsidiary Surgical Lasers Inc., is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions comprise multiple laser systems, consumables, clinical education, service, support and maintenance and focus on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs.

For further information, please contact:

Aquarius Surgical Technologies Inc.
Gary Van Nest, Chief Executive Officer
647-308-0685
email: gary@sinaltainvestments.com

The Canadian Securities Exchange has neither approved nor disapproved of the information contained in this release. This Media Release may contain forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the success of the Corporation's sales strategies.